← Leaderboards
Griffith D. Parks
University Of Central Florida
$8,862,038
Attributed
$8,862,038
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,862,038 · 13
By mechanism
R01$3,577,497 · 2
R21$2,456,162 · 6
P01$2,212,044 · 2
T32$311,848 · 1
R03$304,487 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Paramyxovirus”
- Thomas William Geisbert · Boston University Medical Campus$29,343,162
- Anne Moscona · Mount Sinai School Of Medicine Of Nyu$27,091,846
- Christopher Broder · Henry M. Jackson Fdn For The Adv Mil/Med$19,756,755
- Benhur Lee · University Of Pennsylvania$18,466,031
- Richard K. Plemper · Georgia State University$17,177,113
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
Research focus
ParamyxovirusVirusInfectionViralMediatingInterestCellsRecombinant VirusSimian Virus 5Signal TransductionEngineeringImmune ResponseRna VirusesComplementVirionPathway InteractionsGrowthCytolysisResistanceSignal PathwayMumps VirusInnovationResponseComplement Pathway
Grant awards (44)
Complement Resistance Acquired During Acute to Persistent Rubulavirus Infection$190,172
R21 · FY2024 · AI · contact PI
Complement Resistance Acquired During Acute to Persistent Rubulavirus Infection$241,169
R21 · FY2023 · AI · contact PI
Role of Complement in Nipah Virus Pathogenesis$187,560
R21 · FY2018 · AI · contact PI
Role of Complement in Nipah Virus Pathogenesis$235,560
R21 · FY2017 · AI · contact PI
Paramyxovirus Activation and Inhibition of Complement Pathways$369,968
R01 · FY2015 · AI · contact PI
Paramyxovirus Activation and Inhibition of Complement Pathways$325,126
R01 · FY2014 · AI · contact PI
Paramyxovirus Activation and Inhibition of Complement Pathways$44,874
R01 · FY2014 · AI · contact PI
Paramyxovirus Activation and Inhibition of Complement Pathways$347,800
R01 · FY2013 · AI · contact PI
Training Program in Immunology and Pathogenesis$156,042
T32 · FY2013 · AI · contact PI
Assembly of Live Nipah Virus with Complement Factors$58,462
R03 · FY2013 · AI · contact PI
Assembly of Live Nipah Virus with Complement Factors$21,253
R03 · FY2013 · AI · contact PI
Paramyxovirus Activation and Inhibition of Complement Pathways$370,000
R01 · FY2012 · AI · contact PI
Training Program in Immunology and Pathogenesis$155,806
T32 · FY2012 · AI · contact PI
Assembly of Live Nipah Virus with Complement Factors$81,209
R03 · FY2012 · AI · contact PI
Paramyxovirus Activation and Inhibition of Complement Pathways$382,000
R01 · FY2011 · AI · contact PI
Anti-Bacterial Innate Responses Enhance Paramyxovirus Replication$219,780
R21 · FY2010 · DC · contact PI
Complement-mediated Neutralization of Mumps Virus and SV5$219,602
R21 · FY2010 · AI · contact PI
Complement-mediated Neutralization of Mumps Virus and SV5$81,551
R21 · FY2010 · AI · contact PI
Complement-mediated Neutralization of Mumps Virus and SV5$196,820
R21 · FY2009 · AI · contact PI
Anti-Bacterial Innate Responses Enhance Paramyxovirus Replication$185,000
R21 · FY2009 · DC · contact PI
Novel Vaccine Vectors Based on the Paramyxovirus SV5$347,979
P01 · FY2008 · AI · contact PI
Control of Paramyxovirus RNA Synthesis$233,588
R01 · FY2008 · AI · contact PI
Virology$121,266
P01 · FY2008 · AI · contact PI
Novel Vaccine Vectors Based on the Paramyxovirus SV5$267,441
P01 · FY2007 · AI · contact PI
Control of Paramyxovirus RNA Synthesis$238,112
R01 · FY2007 · AI · contact PI
Virology$150,434
P01 · FY2007 · AI · contact PI
Novel Vaccine Vectors Based on the Paramyxovirus SV5$268,356
P01 · FY2006 · AI · contact PI
Enhancing the Potency of Viral Vectors with C3d$267,987
R21 · FY2006 · AI · contact PI
Control of Paramyxovirus RNA Synthesis$245,224
R01 · FY2006 · AI · contact PI
Virology$150,952
P01 · FY2006 · AI · contact PI
Diversity Supplement: Novel Vaccine Vectors Based on the Paramyxovirus SV5$74,380
P01 · FY2006 · AI · contact PI
Enhancing the Potency of Viral Vectors with C3d$285,836
R21 · FY2005 · AI
Novel Vaccine Vectors Based on the Paramyxovirus SV5$260,923
P01 · FY2005 · AI
Control of Paramyxovirus RNA Synthesis$251,125
R01 · FY2005 · AI
Virology$146,771
P01 · FY2005 · AI
Activation of Apoptosis by a Simian Virus 5 Mutant$71,750
R03 · FY2005 · AI
Novel Vaccine Vectors Based on the Paramyxovirus SV5$271,066
P01 · FY2004 · AI
Control of Paramyxovirus RNA Synthesis$257,189
R01 · FY2004 · AI
Virology$152,476
P01 · FY2004 · AI
Activation of Apoptosis by a Simian Virus 5 Mutant$71,813
R03 · FY2004 · AI
CONTROL OF PARAMYXOVIRUS RNA SYNTHESIS$173,729
R01 · FY2002 · AI
CONTROL OF PARAMYXOVIRUS RNA SYNTHESIS$168,671
R01 · FY2001 · AI
CONTROL OF PARAMYXOVIRUS RNA SYNTHESIS$170,091
R01 · FY2000 · AI
SIMIAN VIRUS 5 AS AN HIV VACCINE VECTOR$145,125
R21 · FY2000 · AI